Recent Updates
Recently added Catalysts

Well-differentiated Non-functional Neuroendocrine Tumor: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$9.0Buniverse median $1.20B
Allocated capital$4.5B$9.0B competing
Phase 3 or filed00 mid, 1 early
Pure plays0this indication only
Capital rank42/299crowding rank 105

Well-differentiated Non-functional Neuroendocrine Tumor is uncontested. Crinetics Pharmaceuticals (CRNX) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with CRN09682 in phase 1.

There is no public comparable to price it against. CRNX spreads its $9.0B market cap across 2 indications, so $4.5B of it is allocated here.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$4.5B of allocated capital sits in Well-differentiated Non-functional Neuroendocrine Tumor, ranking it 42nd of 299 indications by the money committed to it.

Companies developing drugs for Well-differentiated Non-functional Neuroendocrine Tumor 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
CRNXCrinetics PharmaceuticalsCRN09682Phase 11$9.0BNo2No dated event

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Well-differentiated Non-functional Neuroendocrine Tumor counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Well-differentiated Non-functional Neuroendocrine Tumor has one competitor and a median of $9.0B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Biliary Tract Cancer4 companies · $4.6B · median $7.4BConcentrated betChronic Lymphocytic Leukemia4 companies · $3.7B · median $2.1BConcentrated betGastric Cancer8 companies · $3.6B · median $575MKnife fightHead and Neck Cancer7 companies · $5.5B · median $1.8BGold rushRenal Cell Carcinoma5 companies · $3.4B · median $3.8BConcentrated betHER2 Positive Breast Cancer2 companies · $3.3B · median $10.2BConcentrated betBladder Cancer with FGFR3 Mutation1 company · $3.3B · median $6.6BUncontestedColorectal Cancer7 companies · $5.9B · median $723MKnife fight

Well-differentiated Non-functional Neuroendocrine Tumor pipeline questions

Which biotech companies are developing drugs for Well-differentiated Non-functional Neuroendocrine Tumor?

Crinetics Pharmaceuticals (CRNX, CRN09682, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Well-differentiated Non-functional Neuroendocrine Tumor.

How advanced is the Well-differentiated Non-functional Neuroendocrine Tumor pipeline?

Of the 1 clinical-stage programme in Well-differentiated Non-functional Neuroendocrine Tumor, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Well-differentiated Non-functional Neuroendocrine Tumor?

No. CRNX is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Well-differentiated Non-functional Neuroendocrine Tumor, which is why the indication is classified as uncontested.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map